Showing results (11-20 of 332) with videos related to
Sort By:
Pageof 34
Bulletin Du Cancer|May 8, 2026
[Allogeneic stem cell transplantation for persons living with HIV (SFGM-TC)]Anne-Claire Mamez, Ana Berceanu, Patrice Chevallier, et al.Journal of Medical Economics|May 22, 2016
Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart reviewHervé Dombret, Xavier Thomas, Patrice Chevallier, et al.Clinical and Translational Medicine|May 4, 2023
Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplantAmandine Le Bourgeois, Maxime Jullien, Alice Garnier, et al.Bulletin Du Cancer|November 6, 2018
[Post-transplant neurological complications: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]Yosr Hicheri, Nimrod Buchbinder, Leonardo Magro, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 12, 2015
Peripheral Blood Plasmacytoid Dendritic Cells at Day 100 Can Predict Outcome after Allogeneic Stem Cell TransplantationZinaida Peric, Xavier Cahu, Florent Malard, et al.Blood|March 18, 2009
Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host diseaseLeonardo Magro, Mohamad Mohty, Benoit Catteau, et al.Cancer Research|May 23, 2002
Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic originRadek Spisek, Patrice Chevallier, Nadine Morineau, et al.Cancers|April 13, 2024
Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and OutcomeChloé Antier, Maxime Jullien, Benoît Tessoulin, et al.Hematological Oncology|April 25, 2022
Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipientsPatrice Chevallier, Maxime Jullien, Pierre Peterlin, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 2, 2014
Quantification of two viral transcripts by real time PCR to investigate human herpesvirus type 6 active infectionCéline Bressollette-Bodin, Thi Van Ha Nguyen, Marina Illiaquer, et al.Pageof 34